FDA says that anemia drug may harm some patients

Anemia-fighting drugs calling erythropoietins, which totaled more than $10 billion sales in the U.S. last year, may harm some patients. Recent studies showed that physicians using the hormone-like drugs to “cure” the anemia seen in cancer and kidney-failure patients may cause patients to suffer complications and possibly die earlier. The studies showed that physicians are using the drugs at doses beyond those recommended by the FDA.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers